Regeneron Pharmaceuticals Inc. buy Morgan Stanley
Summary
This prediction is currently active. The BUY prediction by Morgan_Stanley currently has a performance of 17.59%. This prediction currently runs until 03.11.24. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 6.540% | 6.540% |
iShares Core DAX® | 3.178% | 0.980% |
iShares Nasdaq 100 | 2.972% | 0.925% |
iShares Nikkei 225® | 0.545% | -4.556% |
iShares S&P 500 | 2.367% | 0.833% |
Comments by Morgan_Stanley for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
18.03.24
18.03.25
22:26
Regeneron Pharmaceuticals Inc.
11.10.23
11.10.24
22:26
Regeneron Pharmaceuticals Inc.
04.08.23
04.08.24
22:26